Abstracts tagged "proteomics and systemic sclerosis"

Abstract Number: 1103 • 2018 ACR/ARHP Annual Meeting
Systemic Sclerosis Has a Distinct Serum Protein Profile That Correlates with Its Clinical Manifestations
Chiara Bellocchi^1,2, Jun Ying³, Ellen Goldmuntz⁴, Lynette Keyes-Elstein⁵, John Varga⁶, Monique Hinchcliff⁶, Peter McSweeney⁷, Daniel E. Furst⁸, Richard Nash⁷, Leslie Crofford⁹, Beverly Welch¹⁰, Ashley Pinckney⁵, Maureen D. Mayes^11,12, Keith Sullivan¹³ and Shervin Assassi¹², ¹University of Texas Health Science Center at Houston, Houston, TX, ²Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ³Department of Internal Medicine - Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴NIAID, National Institutes of Health, Bethesda, MD, ⁵Rho Federal Systems, Inc., Chapel Hill, NC, ⁶Northwestern University, Chicago, IL, ⁷Colorado Blood Cancer Institute, Denver, CO, ⁸University of California Los Angeles, Los Angeles, CA, ⁹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁰National Institutes of Health, Bethesda, MD, ¹¹Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹²Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹³Duke University Medical Center, Durham, NC
Background/Purpose: Proteomic studies with an extensive panel of measured proteins are still scarce in systemic sclerosis (SSc). The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial showed…
Abstract Number: 769 • 2017 ACR/ARHP Annual Meeting
Proteomic Analysis of Human Fibroblasts in Systemic Sclerosis Reinforces the Role of Transforming Growth Factor-ß and Points Toward Epidermal Growth Factor Receptor / Phosphatidylinositol 3 Kinase Pathway Inhibition
Benjamin Chaigne¹, Guilhem Clary², Morgane Le Gall³, Nicolas Dumoitier⁴, Sebastien Lofek⁵, Philippe Chafey², Pia Moinzadeh⁶, Thomas Krieg⁷, Christopher Denton⁸ and Luc Mouthon⁹, ¹Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares d’Ile de France, hôpital Cochin, DHU Authors, Assistance Publique-Hôpitaux de Paris, Paris, France, ²INSERM U1016, Institut Cochin,, Paris, France, ³INSERM U1016 Institut Cochin, Paris, France, ⁴INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ⁵INSERM U1016, paris, France, ⁶Department of Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁷Universität zu Köln, Köln, Germany, ⁸Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁹Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune connective tissue disorder characterized by autoimmunity, vasculopathy and fibrosis. Fibrosis is due to an exaggerated activation of…
Abstract Number: 1917 • 2015 ACR/ARHP Annual Meeting
Developing and Validating a Serum Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis
Lisa Rice¹, Julio Mantero², Giuseppina Stifano¹, Jessica Ziemek³, Robyn T. Domsic⁴ and Robert Lafyatis¹, ¹Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Rheumatology/Arthritis Center, Boston University School of Medicine, Boston, MA, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In this study we aimed to both agonistically investigate alterations in the serum proteome of patients with diffuse cutaneous systemic sclerosis (dcSSc), as well…